DK0476044T3 - Anvendelse af IGF1 eller IGF2 til fremstilling af et lægemiddeltil behandling af amyotrof, lateral sklerose - Google Patents
Anvendelse af IGF1 eller IGF2 til fremstilling af et lægemiddeltil behandling af amyotrof, lateral skleroseInfo
- Publication number
- DK0476044T3 DK0476044T3 DK90909874.1T DK90909874T DK0476044T3 DK 0476044 T3 DK0476044 T3 DK 0476044T3 DK 90909874 T DK90909874 T DK 90909874T DK 0476044 T3 DK0476044 T3 DK 0476044T3
- Authority
- DK
- Denmark
- Prior art keywords
- igf2
- igf1
- amyotrophic
- drug
- preparation
- Prior art date
Links
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 title 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 title 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 201000010901 lateral sclerosis Diseases 0.000 title 1
- 208000005264 motor neuron disease Diseases 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/361,595 US5093317A (en) | 1989-06-05 | 1989-06-05 | Treating disorders by application of insulin-like growth factor |
PCT/US1990/003166 WO1990014838A1 (en) | 1989-06-05 | 1990-06-05 | Treating disorders by application of insulin-like growth factors and analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0476044T3 true DK0476044T3 (da) | 1997-11-17 |
Family
ID=23422661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK90909874.1T DK0476044T3 (da) | 1989-06-05 | 1990-06-05 | Anvendelse af IGF1 eller IGF2 til fremstilling af et lægemiddeltil behandling af amyotrof, lateral sklerose |
Country Status (10)
Country | Link |
---|---|
US (1) | US5093317A (da) |
EP (2) | EP0798000A3 (da) |
JP (1) | JPH0768138B2 (da) |
AT (1) | ATE156018T1 (da) |
CA (1) | CA2058443C (da) |
DE (1) | DE69031168T2 (da) |
DK (1) | DK0476044T3 (da) |
ES (1) | ES2106735T3 (da) |
HK (1) | HK1010989A1 (da) |
WO (1) | WO1990014838A1 (da) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440928B1 (en) | 1988-12-06 | 2002-08-27 | Colorado State University Research Foundation | Method for treating diabetic neuropathy with NGF |
US6723699B1 (en) * | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US6693076B1 (en) * | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5792831A (en) * | 1990-02-08 | 1998-08-11 | Magainin Pharmaceuticals Inc. | Analogues of magainin peptides containing D-amino acids |
US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
US5646120A (en) * | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
US5831001A (en) * | 1990-10-24 | 1998-11-03 | Allelix Biopharmaceuticals Inc. | Treatment of herpesvirus infection |
US5633230A (en) * | 1990-10-24 | 1997-05-27 | Allelix Biopharmaceuticals, Inc. | Treatment of cytomegalovirus infection |
US5674849A (en) * | 1990-10-24 | 1997-10-07 | Allelix Biopharmaceuticals Inc. | Anti-viral compositions |
US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
US6949505B1 (en) * | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
SE9101341D0 (sv) * | 1991-05-03 | 1991-05-03 | Kabi Pharmacia Ab | New medicinal use |
US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
CA2114251C (en) | 1991-08-01 | 2007-11-06 | Peter Gluckman | Igf-1 to improve the neural condition |
US5925564A (en) * | 1991-11-06 | 1999-07-20 | Baylor College Of Medicine | Expression vector systems and method of use |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US6310040B1 (en) * | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
US6204240B1 (en) * | 1991-11-22 | 2001-03-20 | Genentech, Inc. | TGF-β1 to improve neural outcome |
WO1993010806A1 (en) * | 1991-11-25 | 1993-06-10 | Institute Of Molecular Biology, Inc. | Medicament for promoting growth of mammalian nerve |
US5281582A (en) * | 1992-02-27 | 1994-01-25 | Alliance Pharmaceuticals, Corp. | Serum growth factor |
AU4238493A (en) * | 1992-05-08 | 1993-12-13 | Thomas Jefferson University | IGF-1 analogs |
DK0659083T3 (da) * | 1992-06-12 | 2000-06-13 | Einstein Coll Med | Forebyggelse og behandling af perifer neuropati |
US20070078089A1 (en) * | 1992-07-06 | 2007-04-05 | Ishii Douglas N | Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II |
WO1994017818A1 (en) * | 1993-02-08 | 1994-08-18 | The Syntex-Synergen Neuroscience Joint Venture | Methods for treating amyotrophic lateral sclerosis with cntf |
JPH09509140A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 神経学的障害の治療方法 |
WO1995016703A1 (en) * | 1993-12-15 | 1995-06-22 | Thomas Jefferson University | Igf-1 analogs |
US5629286A (en) * | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
US5444047A (en) * | 1994-06-16 | 1995-08-22 | Dipasquale; Gene | Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
US5650496A (en) * | 1995-04-14 | 1997-07-22 | Cephalon, Inc. | IGF-I purification process |
US6756484B1 (en) | 1995-04-14 | 2004-06-29 | Cephalon, Inc. | IGF-I purification process |
US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
EP0766966A3 (en) * | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
WO1997011959A1 (en) * | 1995-09-29 | 1997-04-03 | Receptron, Inc. | Biologically active mhc peptides having a repeated amino acid sequence motif |
ES2196194T3 (es) * | 1995-12-13 | 2003-12-16 | Aurogen Inc | Igf-i y -ii destinados al tratamiento de enfermedades del sistema nervioso central. |
US5798715A (en) * | 1996-06-28 | 1998-08-25 | Saperstone; Dorothy Luhr | Method and device for accessing remote control functions |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
EP1011683A4 (en) | 1997-05-22 | 2003-06-11 | Cephalon Inc | VITAMIN D ANALOGS AND THEIR EFFECTS ON NEURONS |
US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
ES2146530B1 (es) * | 1997-12-26 | 2001-04-16 | Consejo Superior Investigacion | Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar. |
US7118752B2 (en) * | 1998-07-22 | 2006-10-10 | University Of Connecticut | Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I |
US6358916B1 (en) | 1998-07-22 | 2002-03-19 | Thomas T. Chen | Biological activity of IGF-I E domain peptide |
US7700353B2 (en) * | 1998-07-22 | 2010-04-20 | E-P Therapeutics, Inc. | Compositions and methods for inducing apoptosis in tumor cells |
AU5195699A (en) * | 1998-08-11 | 2000-03-06 | Sumitomo Pharmaceuticals Company, Limited | Blood sugar level controlling agent |
DK1141014T3 (da) * | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
RU2278123C2 (ru) * | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
ATE389416T1 (de) | 2000-05-16 | 2008-04-15 | Genentech Inc | Behandlung von knorpelerkrankungen |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
AU8844301A (en) * | 2000-08-29 | 2002-03-13 | Univ Colorado State Res Found | Method for treating the central nervous system by administration of igf structural analogs |
US20020082215A1 (en) * | 2000-10-13 | 2002-06-27 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
AU2002246619A1 (en) * | 2000-12-08 | 2003-06-23 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
HUP0500733A3 (en) * | 2001-02-09 | 2010-01-28 | Genentech Inc | Crystallization of igf-1 |
US7714020B2 (en) * | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
AU2002303856A1 (en) | 2001-05-24 | 2002-12-03 | Neuronz Limited | Gpe analogs and peptidomimetics |
US7605177B2 (en) * | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
TWI305778B (en) * | 2001-12-03 | 2009-02-01 | Nishida Teruo | Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use |
JP4253743B2 (ja) * | 2001-12-03 | 2009-04-15 | 輝夫 西田 | 新規ペプチドおよびその医薬用途 |
ES2207387B1 (es) * | 2002-02-28 | 2005-07-16 | Consejo Sup. Investig. Cientificas | Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas. |
SI1499719T1 (sl) * | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
US20060166874A1 (en) * | 2002-09-30 | 2006-07-27 | Haaning Jesper M | Fvii or fviia variants having increased clotting activity |
US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
DK2085470T3 (da) * | 2003-03-20 | 2012-08-06 | Bayer Healthcare Llc | FVII- eller FVIIa-varianter |
CN1839203B (zh) * | 2003-06-19 | 2011-11-16 | 拜耳医药保健有限公司 | 因子VII或VIIa的GLA结构域变体 |
NZ553057A (en) * | 2004-08-30 | 2009-12-24 | Tercica Inc | Method and device for diagnosing and treating insulin-like growth factor deficiency disorders |
US20060069008A1 (en) * | 2004-09-28 | 2006-03-30 | Sanjay Mistry | Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
US20060069009A1 (en) * | 2004-09-28 | 2006-03-30 | Messina Darin J | Treatment of neurological deficits in the striatum or substanta nigra pars compacta |
EP1846021A2 (en) * | 2005-02-08 | 2007-10-24 | Japan As Represented By The President Of National Cardiovascular Center | Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1) |
JP2008533114A (ja) * | 2005-03-18 | 2008-08-21 | ユーシーエル ビジネス パブリック リミテッド カンパニー | メカノ成長因子ペプチドおよびその使用 |
CL2007002502A1 (es) * | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
ES2322685B2 (es) * | 2006-11-21 | 2010-03-15 | Universidad De Malaga | Utilizacion de dosis bajas de igf-ii en el envejecimiento por sus efectos neuroprotectores y hepatoprotectores. |
EP2164509A1 (en) * | 2007-06-08 | 2010-03-24 | Massachusetts Institute of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
AU2009231394B2 (en) * | 2008-04-03 | 2013-09-05 | F. Hoffmann-La Roche Ag | Use of PEGylated IGF-I variants for the treatment of neuromuscular disorders |
TWI541020B (zh) | 2008-04-17 | 2016-07-11 | 巴克斯歐塔公司 | 生物活性胜肽 |
EP3209306B1 (en) | 2014-10-20 | 2024-04-24 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
EP3299023A4 (en) * | 2015-05-21 | 2019-03-20 | Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences | MESENCHYMAL SUBSTITUTE CELL CULTIVATED IN HYPOXIA AND USE THEREOF |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4341762A (en) * | 1981-04-07 | 1982-07-27 | Haast William E | Use of snake venoms for treatment of neurological and related disorders |
JPS5965058A (ja) * | 1982-10-05 | 1984-04-13 | Daiichi Rajio Isotope Kenkyusho:Kk | ヘンエイコサペプチド |
US4699875A (en) * | 1982-11-24 | 1987-10-13 | Baylor College Of Medicine | Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors |
US4511390A (en) * | 1983-06-10 | 1985-04-16 | E. I. Du Pont De Nemours And Company | Aralkylcarbamoyl peptide alcohols |
WO1988001693A1 (en) * | 1986-09-05 | 1988-03-10 | Young Niels O | Magnet ball pump |
US4783524A (en) * | 1985-09-17 | 1988-11-08 | Monsanto Company | Growth factors |
SE8505920D0 (sv) * | 1985-12-13 | 1985-12-13 | Kabigen Ab | New protein and its use |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4751645A (en) * | 1986-08-12 | 1988-06-14 | Abrams William R | Method for sonic analysis of an anomaly in a seafloor topographic representation |
GB8624560D0 (en) * | 1986-10-14 | 1986-11-19 | Bp Chem Int Ltd | Polymer polyols |
JPS63196524A (ja) * | 1987-02-10 | 1988-08-15 | Wakunaga Pharmaceut Co Ltd | 経粘膜吸収型制ガン作用調節剤 |
DE3851776T2 (de) * | 1987-04-28 | 1995-05-04 | Boehringer Mannheim Gmbh | Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. |
US5004697A (en) * | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
CA1338337C (en) * | 1988-09-27 | 1996-05-21 | Health Foundation Limited (The) | Method and composition for the treatment of burns |
WO1991002067A1 (en) * | 1989-07-27 | 1991-02-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulation of nerve growth factor synthesis in the central nervous system |
-
1989
- 1989-06-05 US US07/361,595 patent/US5093317A/en not_active Expired - Lifetime
-
1990
- 1990-06-05 JP JP2509846A patent/JPH0768138B2/ja not_active Expired - Lifetime
- 1990-06-05 AT AT90909874T patent/ATE156018T1/de not_active IP Right Cessation
- 1990-06-05 EP EP97200539A patent/EP0798000A3/en not_active Withdrawn
- 1990-06-05 WO PCT/US1990/003166 patent/WO1990014838A1/en active IP Right Grant
- 1990-06-05 DE DE69031168T patent/DE69031168T2/de not_active Expired - Lifetime
- 1990-06-05 DK DK90909874.1T patent/DK0476044T3/da active
- 1990-06-05 EP EP90909874A patent/EP0476044B1/en not_active Expired - Lifetime
- 1990-06-05 ES ES90909874T patent/ES2106735T3/es not_active Expired - Lifetime
- 1990-06-05 CA CA002058443A patent/CA2058443C/en not_active Expired - Lifetime
-
1998
- 1998-11-16 HK HK98112043A patent/HK1010989A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE156018T1 (de) | 1997-08-15 |
JPH0768138B2 (ja) | 1995-07-26 |
WO1990014838A1 (en) | 1990-12-13 |
EP0798000A3 (en) | 1998-01-14 |
EP0476044B1 (en) | 1997-07-30 |
JPH04507240A (ja) | 1992-12-17 |
DE69031168T2 (de) | 1997-12-04 |
DE69031168D1 (de) | 1997-09-04 |
CA2058443A1 (en) | 1990-12-06 |
EP0798000A2 (en) | 1997-10-01 |
HK1010989A1 (en) | 1999-07-02 |
EP0476044A1 (en) | 1992-03-25 |
CA2058443C (en) | 1998-11-03 |
EP0476044A4 (en) | 1992-07-01 |
US5093317A (en) | 1992-03-03 |
ES2106735T3 (es) | 1997-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0476044T3 (da) | Anvendelse af IGF1 eller IGF2 til fremstilling af et lægemiddeltil behandling af amyotrof, lateral sklerose | |
EP0602700A3 (en) | Preparation of X-ray contrasting formulations for blood containing high molecular weight surfactant nanoparticles. | |
EP0552256A4 (da) | ||
ATE493998T1 (de) | Pharmazeutische zusammensetzung mit einem exendin-4-peptid | |
CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
EE05492B1 (et) | Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral | |
DE1033998T1 (de) | Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer | |
MX9101175A (es) | Composicion farmaceutica para administracion nasal | |
NO864556L (no) | Fremgangsmaate ved fremstilling av insulinpreparat. | |
CH680983C9 (da) | ||
DK0470117T3 (da) | Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner | |
ATE56138T1 (de) | Perfluorkohlenwasserstoffe als vehikel zur verabreichung von arzneimitteln. | |
DK0667768T3 (da) | Anvendelse af toremifen til behandling af SLE | |
DE69100171D1 (de) | Synergistische kombination zur ophthalmischen verwendung. | |
SE9101687L (sv) | Dikloranilinfoerening | |
DE69000791D1 (de) | Therapeutische mittel fuer metabolische knochenkrankheiten. | |
DE3878154D1 (de) | Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid. | |
IL101540A0 (en) | Method and composition for the treatment of herpes related disorders | |
ATE9903T1 (de) | 3-amino-5-substituierte 6-halo-n-(3,4-dihydrooder 4,4-disubstituierte-6-substituierte 1,3,5- triazin-2-yl)-pyrazin-carboxamide, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate. | |
IT9041714A0 (it) | Linfa del libro dell'abete rosso (abies picea) per la cura di malattie neoplastiche e da virus in genere | |
ES1015784Y (es) | Nuevo envase para calzados infantiles. | |
DK250890D0 (da) | Canister til inhalationsmedicin | |
ATE31315T1 (de) | Inklusionscomplexe von n-(1-phenylaethyl)-3,3diphenylpropylamin bzw. dessen hydrochlorid mit cyclodextrin, verfahren zur herstellung dieser inklusionskomplexe sowie diese inklusionskomplexe enthaltende pharmazeutische praeparate. | |
IT8819665A0 (it) | (1,2_di_0_acetil_glicero_3_fosforil)_colina, procedimento per la sua preparazione e suo uso terapeutico. |